SOPHiA GENETICS (NASDAQ:SOPH) Insider Well Daan Van Sells 2,861 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Daan Van sold 2,861 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $4.85, for a total value of $13,875.85. Following the transaction, the insider directly owned 350,808 shares in the company, valued at $1,701,418.80. This represents a 0.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, April 9th, Well Daan Van sold 1,988 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,423.12.
• On Monday, April 6th, Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $13,146.30.
• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $3,276.36.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $4.70 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The firm has a market cap of $321.90 million, a price-to-earnings ratio of -9.22 and a beta of 1.04. The business’s fifty day moving average is $4.75 and its 200 day moving average is $4.69.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Research analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Guggenheim boosted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research reiterated a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.00.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC increased its stake in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth about $6,708,000. Royce & Associates LP bought a new position in SOPHiA GENETICS in the 4th quarter worth about $2,009,000. Finally, 1492 Capital Management LLC bought a new position in SOPHiA GENETICS in the 4th quarter worth about $973,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.